Furthermore, more varieties of cancers (bladder, ovarian, uterine, liver, cervical, esophageal, breast cancers, sarcoma, diffuse large B-cell lymphoma, etc.)are estimated to carry RB1-SUCLA2 deletion with up to 5% prevalence [100]. Here, SUCLA2 is linked to cancer.